viewAvalon GloboCare Corp

Avalon GloboCare launches first-in-human study of AVA-001 for leukemia, non-Hodgkin lymphoma

The study of AVA-001 is being conducted at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China

Avalon is focused on advancing cellular therapeutics utilizing exosomes, vesicles that sit outside and operate between cells

Avalon GloboCare Corp (NASDAQ:AVCO) on Monday provided an update of four clinical programs in cellular therapy, noting that AVA-001 entered into this month the first-in-human clinical study for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma.

The study of AVA-001, which is a leverage individualized CAR (Chimeric Antigen Receptor) T-cell therapy candidate for immuno-oncology, is being conducted at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China, the world’s single largest CAR-T treatment network with over 600 patients.

The significance of CAR-T cells is that they have been engineered to express a receptor (CAR) that recognizes a specific cancer surface target to attack. Unlike traditional small molecule or biologic treatments, the CAR-T therapies are specifically manufactured for each individual patient.

READ:Avalon GloboCare adds Cornell cellular therapy director to its advisory board

Avalon said the clinical trial of AVA-001 could result in a more powerful delivery mechanism designed to treat the individual patient. The company expects to recruit 20 patients for safety and efficacy studies of AVA-001.

The company also said its proprietary, transposon-based, multi-targeted CAR-T candidate, AVA-101, will enter the pre-clinical process development and validation phase during the third quarter of 2019 as scheduled.

Avalon, based in Freehold, New Jersey, said it could launch the first-in-human clinical trial of this next-generation of safer and more efficacious CAR-T candidate during first quarter of 2020.

The company has further developed a novel therapeutic candidate, AVA-201, for oral cancer. The company plans to launch the first-in-human clinical trial for AVA-201 during the fourth quarter of 2019 with the expectation to move toward a regulatory filing in the fourth quarter of 2020.

Treating diabetic foot ulcer

Lastly, Avalon said it is developing a clinical-grade, exosome-based therapeutic candidate, AVA-202, and plans to initiate international multi-centered clinical studies of vascular diseases and wound healing, including treatment of diabetic foot ulcer, during the fourth quarter of 2019.

“We are pleased to provide updates on our progress in advancing clinical studies using our cellular therapeutic platforms in CAR-T and stem cell derived exosomes,” said CEO Dr David Jin.

“We have successfully evolved into an active clinical stage company which we have the technology, partnerships and talent, all committed to delivering clinical execution and leadership in the areas of cellular immunotherapy and exosome technology.”

Avalon’s stock recently traded up 4.1% to $2.13 a share.

Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham

Quick facts: Avalon GloboCare Corp

Price: 1.75 USD

Market: NASDAQ
Market Cap: $138.89 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...



Avalon Globocare Corp seeing success working in the celltech space

Avalon GloboCare CEO (NASDAQ:AVCO) Dr. David Jin sat down with Proactive's Steve Darling at the 12th annual LD Micro Conference. The company is a clinical-stage CellTech bio-developer specializing in cellular therapeutics. Dr Jin talked about success in 2019 and what he expects in 2020.

on 12/10/2019

2 min read